All In Biotech

Free tool

FAERS Monitor: Rhopressa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208254 or its brand name (Rhopressa, Netarsudil Mesylate). Reports on generic versions are filed under their own applications.

Reports

1,971

Serious

434

22% of reports

Hospitalization

105

Death reported

63

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • conjunctival hyperaemia246
  • vision blurred165
  • ocular hyperaemia162
  • off label use158
  • eye pain149
  • eye irritation123
  • product dose omission issue98
  • corneal oedema95
  • intraocular pressure increased95
  • lacrimation increased94
  • visual acuity reduced89
  • drug ineffective79
  • eye pruritus70
  • cornea verticillata60
  • headache57

Reports by year received

View as table
YearReports
20171
2018145
2019470
2020253
2021111
2022137
2023244
2024210
2025227
2026173

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,188 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cornea verticillataSignal602626.51987.1124,292
conjunctival hyperaemiaSignal246790.9700.3179,995
corneal oedemaSignal95472.4386.542,349
intraocular pressure increasedSignal9579.965.67,274
ocular hyperaemiaSignal16236.531.55,559
lacrimation increasedSignal9433.327.32,908
visual acuity reducedSignal8928.723.42,347
eye painSignal14928.324.23,890
eye irritationSignal12322.919.32,550
eye pruritusSignal7022.317.71,401
vision blurredSignal16512.811.11,799
product dose omission issueSignal983.62.9180
off label use1581.91.772
headache571.00.80
drug ineffective790.60.517

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.